The future of drug eluting stents

RR Anis, KR Karsch

Research output: Contribution to journalArticle (Academic Journal)peer-review

17 Citations (Scopus)


ABSTRACT In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10–40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation. Recently, new stents have emerged that are loaded with anti-inflammatory, antimigratory, antiproliferative, or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently ISR. The future of DES lies in the development of better stents with new stent designs, better polymers including biological polymers and biological biodissolvable stent coatings, and new, better drugs.
Translated title of the contributionThe future of drug eluting stents
Original languageEnglish
Pages (from-to)585 - 588
Number of pages4
Publication statusPublished - May 2006

Bibliographical note

Publisher: BMJ Publishing Group


Dive into the research topics of 'The future of drug eluting stents'. Together they form a unique fingerprint.

Cite this